{"log_id": 8364038027907364421, "direction": 0, "words_result_num": 46, "words_result": [{"probability": {"variance": 0.006241, "average": 0.967808, "min": 0.622236}, "location": {"width": 868, "top": 186, "height": 22, "left": 227}, "words": "中性粒细胞减少是多西他赛治疗最常见的不良反应。中性粒细胞减少至最低点的中位时间为7天,但此间躺在多次治"}, {"probability": {"variance": 0.018607, "average": 0.933473, "min": 0.375239}, "location": {"width": 840, "top": 216, "height": 25, "left": 193}, "words": "疗的患者中可细。对所有多西他治疗的患者应经常进行全血细胞计数监测。当忠者的中性粒纠胞计数恢复"}, {"probability": {"variance": 0.003632, "average": 0.965855, "min": 0.739506}, "location": {"width": 477, "top": 248, "height": 22, "left": 192}, "words": "≥1500/mm3以上时才能接受多西他赛的治疗(见【用法用量】)。"}, {"probability": {"variance": 0.016733, "average": 0.939983, "min": 0.443885}, "location": {"width": 870, "top": 278, "height": 26, "left": 227}, "words": "多西他赛治疗期间如果发生重度的中性拉细胞减少(<500/m3持续7天或以上).推荐在下一个疗程中减少剂觉或"}, {"probability": {"variance": 0.010928, "average": 0.964813, "min": 0.538192}, "location": {"width": 296, "top": 310, "height": 23, "left": 193}, "words": "采用适当的对症处理(见【用法用量】)"}, {"probability": {"variance": 0, "average": 0.999615, "min": 0.999392}, "location": {"width": 68, "top": 342, "height": 20, "left": 192}, "words": "过敏反应"}, {"probability": {"variance": 0.005887, "average": 0.970839, "min": 0.644903}, "location": {"width": 872, "top": 372, "height": 27, "left": 225}, "words": "应密切注心患者的过敏反应,特别是在第1次及第2次输注时:在多西他赛开始输注的最初几分钟内有可能发生过敏"}, {"probability": {"variance": 0.02128, "average": 0.930001, "min": 0.384978}, "location": {"width": 902, "top": 403, "height": 28, "left": 193}, "words": "反应,因此应准备好治疗低血压及文气管烧挛的设备。己有报导,在接受过化疗前用药的忠者中,也会发生重度过敏反"}, {"probability": {"variance": 0.023108, "average": 0.911801, "min": 0.480057}, "location": {"width": 892, "top": 435, "height": 27, "left": 192}, "words": "应,如全身皮疹/红斑,垂度低血压,文气管痉挛或罕见的致命的过敏性反应,发生过敏反应需立即停止输注井进行对症"}, {"probability": {"variance": 0.001947, "average": 0.977172, "min": 0.78598}, "location": {"width": 444, "top": 468, "height": 21, "left": 193}, "words": "治疗。对已发生重度过敏反应的患者不能再次应用多西他赛"}, {"probability": {"variance": 3.3e-05, "average": 0.996154, "min": 0.986221}, "location": {"width": 70, "top": 499, "height": 20, "left": 192}, "words": "皮肤反应"}, {"probability": {"variance": 0.008609, "average": 0.948622, "min": 0.597292}, "location": {"width": 868, "top": 528, "height": 29, "left": 227}, "words": "观察到肢体来端(手掌及脚趾)发生局部皮肤红斑伴水肿维而脱皮现象。有报导因重度症状如皮疹继而脱皮导致于扰或"}, {"probability": {"variance": 0.040548, "average": 0.889485, "min": 0.418243}, "location": {"width": 279, "top": 561, "height": 22, "left": 193}, "words": "中渐多西仙赛治疗(见【用法用】)"}, {"probability": {"variance": 2.6e-05, "average": 0.991708, "min": 0.986029}, "location": {"width": 68, "top": 593, "height": 20, "left": 193}, "words": "体液潴留"}, {"probability": {"variance": 0.006803, "average": 0.963372, "min": 0.540958}, "location": {"width": 580, "top": 622, "height": 28, "left": 224}, "words": "思者可能发生重度体液潴留,应切注意如胸膜积液,心包积液及腹水的发生"}, {"probability": {"variance": 0.000934, "average": 0.984636, "min": 0.899625}, "location": {"width": 158, "top": 655, "height": 21, "left": 188}, "words": "肝功能有损害的患者"}, {"probability": {"variance": 0.015304, "average": 0.951124, "min": 0.390277}, "location": {"width": 867, "top": 687, "height": 25, "left": 224}, "words": "使用多西他赛单药治疗100mg/m2剂量的者,如果血清氨转移酶(ALT和/或AST)超过1.5倍正常值上限,同时伴"}, {"probability": {"variance": 0.011987, "average": 0.933496, "min": 0.517983}, "location": {"width": 891, "top": 717, "height": 28, "left": 192}, "words": "有碱性磷酸酶超过2.5倍正常值上限,发生重度不良反应的危险性升高,如因毒性死亡,包括致死的脓毒症和胃肠道山血"}, {"probability": {"variance": 0.018007, "average": 0.917112, "min": 0.481}, "location": {"width": 901, "top": 748, "height": 30, "left": 193}, "words": "发热性中性拉细胞减少症,感染、血小板减少症,口腔炎和乏力。因此,这些肝功能化验值(LFTs)升高的患者,其多西他"}, {"probability": {"variance": 0.010589, "average": 0.950532, "min": 0.54675}, "location": {"width": 690, "top": 781, "height": 26, "left": 194}, "words": "赛的推荐剂量为75mg/m2.井且在线和每个周期前要检测肝功能(LFTs)(见【用法用量】)"}, {"probability": {"variance": 0.01225, "average": 0.947771, "min": 0.496812}, "location": {"width": 870, "top": 813, "height": 28, "left": 224}, "words": "当患者血清胆红紧>正常值上限且/或ALT及AST>3.5倍正常值上伴血清碱性磷酸酶>6倍正常值上限,除非有严格"}, {"probability": {"variance": 0.00965, "average": 0.962122, "min": 0.561069}, "location": {"width": 365, "top": 846, "height": 21, "left": 192}, "words": "的使用指证,否则不应使用,也无减量使用建议"}, {"probability": {"variance": 0.009867, "average": 0.949621, "min": 0.641844}, "location": {"width": 451, "top": 877, "height": 23, "left": 225}, "words": "目前尚无严重肝功能损害患者使用多西他赛联合用药的资料"}, {"probability": {"variance": 0.00841, "average": 0.944081, "min": 0.702142}, "location": {"width": 153, "top": 909, "height": 21, "left": 191}, "words": "肾功能有损害的患者"}, {"probability": {"variance": 0.013842, "average": 0.947749, "min": 0.45418}, "location": {"width": 382, "top": 941, "height": 23, "left": 224}, "words": "甘前尚无严重肾功能损害患者使用多西他赛的资料"}, {"probability": {"variance": 0.000406, "average": 0.987138, "min": 0.952272}, "location": {"width": 71, "top": 972, "height": 23, "left": 192}, "words": "神经系统"}, {"probability": {"variance": 0.002547, "average": 0.970745, "min": 0.796493}, "location": {"width": 590, "top": 1004, "height": 25, "left": 224}, "words": "当观察到重度外周神经毒性症状时,应减少多西他赛的剂量(见【用法用量】)"}, {"probability": {"variance": 3e-05, "average": 0.995624, "min": 0.986313}, "location": {"width": 68, "top": 1038, "height": 21, "left": 194}, "words": "心脏毒性"}, {"probability": {"variance": 0.019289, "average": 0.926744, "min": 0.360004}, "location": {"width": 863, "top": 1068, "height": 28, "left": 229}, "words": "在接受多西他赛联合曲妥珠单抗治疗的患中,特别是在含环类药物治疗(阿霉素或表阿霉素)后,观察到心力竭"}, {"probability": {"variance": 0.000151, "average": 0.993066, "min": 0.943966}, "location": {"width": 484, "top": 1101, "height": 24, "left": 190}, "words": "发生,可能是中度至重度的,并可能导致死亡(见【不良反应】)"}, {"probability": {"variance": 0.017767, "average": 0.937042, "min": 0.492331}, "location": {"width": 859, "top": 1131, "height": 29, "left": 224}, "words": "当患者准备接受多西他赛联合曲买珠单抗治疗时,应对代基础心脏状况进行评估。在治疗期间应维续监测心脏功能"}, {"probability": {"variance": 0.012016, "average": 0.955118, "min": 0.446347}, "location": {"width": 687, "top": 1165, "height": 24, "left": 193}, "words": "(如:每3个月).有助于确诊想者是否发生心脏机能紊乱。更多的详情见曲买珠单抗说明书。"}, {"probability": {"variance": 0, "average": 0.99755, "min": 0.996843}, "location": {"width": 34, "top": 1196, "height": 22, "left": 190}, "words": "其他"}, {"probability": {"variance": 0.004049, "average": 0.967904, "min": 0.748908}, "location": {"width": 411, "top": 1228, "height": 23, "left": 230}, "words": "在治疗期间及治疗结束后至少三个月内应采取避孕措施"}, {"probability": {"variance": 0.032175, "average": 0.925417, "min": 0.450249}, "location": {"width": 261, "top": 1261, "height": 23, "left": 191}, "words": "乳腺痛辅助化疗时的其他注意事项"}, {"probability": {"variance": 0.021533, "average": 0.543523, "min": 0.396783}, "location": {"width": 42, "top": 1266, "height": 38, "left": 943}, "words": "宝"}, {"probability": {"variance": 0.010395, "average": 0.949705, "min": 0.663623}, "location": {"width": 147, "top": 1294, "height": 22, "left": 193}, "words": "并发中性粒细胞减少"}, {"probability": {"variance": 0.017693, "average": 0.927265, "min": 0.463281}, "location": {"width": 869, "top": 1325, "height": 27, "left": 224}, "words": "并发中性粒细胞减少的思者(包括中性粒细胞减少发生时间延长,发热性中性拉细业减少,或感染):应考虑使用G-CSF"}, {"probability": {"variance": 0.007117, "average": 0.955869, "min": 0.700789}, "location": {"width": 224, "top": 1358, "height": 21, "left": 192}, "words": "及减少剂量(见【用法用量】)"}, {"probability": {"variance": 0.016698, "average": 0.916949, "min": 0.662105}, "location": {"width": 85, "top": 1390, "height": 21, "left": 194}, "words": "胃肠道反应"}, {"probability": {"variance": 0.008657, "average": 0.964752, "min": 0.559562}, "location": {"width": 867, "top": 1420, "height": 27, "left": 223}, "words": "早期出现的症状包括:伴或不伴中性粒细胞减少的腹痛及胃肠道敏感,发热,腹泻。早期可能发生严重胃肠道毒性反"}, {"probability": {"variance": 8e-06, "average": 0.998252, "min": 0.992241}, "location": {"width": 170, "top": 1454, "height": 21, "left": 191}, "words": "应,应迅速诊断及治疗"}, {"probability": {"variance": 0.007364, "average": 0.950579, "min": 0.744075}, "location": {"width": 120, "top": 1486, "height": 22, "left": 193}, "words": "充血性心力衰竭"}, {"probability": {"variance": 0.006875, "average": 0.966877, "min": 0.53948}, "location": {"width": 859, "top": 1517, "height": 29, "left": 224}, "words": "在治疗及访期问,应对患者充血性心衰的症状进行监测。在接受TAC治疗的淋巴结阳性乳腺痛患者中观察到治疗"}, {"probability": {"variance": 0.008988, "average": 0.944075, "min": 0.683129}, "location": {"width": 160, "top": 1550, "height": 23, "left": 190}, "words": "后第一年的CHF较高"}, {"probability": {"variance": 1.6e-05, "average": 0.982894, "min": 0.977819}, "location": {"width": 53, "top": 1586, "height": 20, "left": 194}, "words": "白血病"}], "language": 3}